AIRLINK 79.41 Increased By ▲ 1.02 (1.3%)
BOP 5.33 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.38 Increased By ▲ 0.05 (1.15%)
DFML 33.19 Increased By ▲ 2.32 (7.52%)
DGKC 76.87 Decreased By ▼ -1.64 (-2.09%)
FCCL 20.53 Decreased By ▼ -0.05 (-0.24%)
FFBL 31.40 Decreased By ▼ -0.90 (-2.79%)
FFL 9.85 Decreased By ▼ -0.37 (-3.62%)
GGL 10.25 Decreased By ▼ -0.04 (-0.39%)
HBL 117.93 Decreased By ▼ -0.57 (-0.48%)
HUBC 134.10 Decreased By ▼ -1.00 (-0.74%)
HUMNL 7.00 Increased By ▲ 0.13 (1.89%)
KEL 4.67 Increased By ▲ 0.50 (11.99%)
KOSM 4.74 Increased By ▲ 0.01 (0.21%)
MLCF 37.44 Decreased By ▼ -1.23 (-3.18%)
OGDC 136.70 Increased By ▲ 1.85 (1.37%)
PAEL 23.15 Decreased By ▼ -0.25 (-1.07%)
PIAA 26.55 Decreased By ▼ -0.09 (-0.34%)
PIBTL 7.00 Decreased By ▼ -0.02 (-0.28%)
PPL 113.75 Increased By ▲ 0.30 (0.26%)
PRL 27.52 Decreased By ▼ -0.21 (-0.76%)
PTC 14.75 Increased By ▲ 0.15 (1.03%)
SEARL 57.20 Increased By ▲ 0.70 (1.24%)
SNGP 67.50 Increased By ▲ 1.20 (1.81%)
SSGC 11.09 Increased By ▲ 0.15 (1.37%)
TELE 9.23 Increased By ▲ 0.08 (0.87%)
TPLP 11.56 Decreased By ▼ -0.11 (-0.94%)
TRG 72.10 Increased By ▲ 0.67 (0.94%)
UNITY 24.82 Increased By ▲ 0.31 (1.26%)
WTL 1.40 Increased By ▲ 0.07 (5.26%)
BR100 7,526 Increased By 32.9 (0.44%)
BR30 24,650 Increased By 91.4 (0.37%)
KSE100 71,971 Decreased By -80.5 (-0.11%)
KSE30 23,749 Decreased By -58.8 (-0.25%)
World

South Korea suspends AstraZeneca shots for people under 60 amid European review

  • The European Medical Agency (EMA) is due to announce the results of a review on whether some cases of blood clotting in adults may be linked to the AstraZeneca shot.
  • South Korea's food and drug safety ministry said on Wednesday it had granted final approval for Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot was safe and effective.
Published April 7, 2021

SEOUL: South Korea said on Wednesday it will temporarily suspend providing AstraZeneca's COVID-19 vaccine to people below 60 amid a European review, while approving a Johnson & Johnson shot in a bid to speed up its inoculation rollout.

The European Medical Agency (EMA) is due to announce the results of a review on whether some cases of blood clotting in adults may be linked to the AstraZeneca shot.

The announcement is due at 1400 GMT.

Global controversy over the efficacy and side-effects of some COVID-19 vaccines has caused some delays in South Korea's vaccination campaign, which kicked off in late February with the goal of reaching herd immunity in November.

AstraZeneca has said previously its studies have found no higher risk of clots because of its vaccine, millions of doses of which have been administered worldwide. The World Health Organization and EMA have both said the benefits outweigh the risks.

South Korea's food and drug safety ministry said on Wednesday it had granted final approval for Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot was safe and effective.

J&J is the third COVID-19 vaccine maker to be authorised in South Korea, after AstraZeneca and Pfizer /BioNTech, both of which require two doses.

Authorities are seeking to speed up a national vaccination campaign despite global supply shortages while expanding preemptive testing and tracing efforts amid concerns over a potential fourth wave of infections.

The Korea Disease Control and Prevention Agency (KDCA) reported 668 new cases for Tuesday, the highest level since Jan. 8, with clusters developing in kindergartens, saunas, bars and churches, mostly in the greater Seoul area.

To date, total infections stand at 106,898, with 1,756 deaths.

"If the fourth wave of infections becomes a reality, a disruption to vaccination would be inevitable, as well as dealing a big blow to our economy," Prime Minister Chung Sye-kyun told a government meeting.

Health officials called on the public to refrain from non-essential gatherings and strictly log visits to crowded venues to help with epidemiological work in case of any outbreak.

They also said they would announce new social distancing rules on Friday after discussion with experts and local governments.

The country has so far administered over a million doses of vaccine among medical workers and high-risk groups since the start of its inoculation drive in February, yet authorities face a backlash for relying on the global vaccine-sharing programme COVAX, which has run into delays.

Comments

Comments are closed.